

Dystrophic Epidermolysis Bullosa Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2033

<https://marketpublishers.com/r/DF050A072A6DEN.html>

Date: March 2023

Pages: 285

Price: US\$ 5,499.00 (Single User License)

ID: DF050A072A6DEN

Abstracts

The dystrophic epidermolysis bullosa market size in top seven countries reached US\$ 466.1 Million in 2022. Looking forward, IMARC Group expects the market in top seven countries to reach US\$ 1,582.7 Million by 2033, exhibiting a growth rate (CAGR) of 12.90% during 2023-2033.

The Dystrophic Epidermolysis Bullosa Market has been comprehensively analyzed in IMARC's new report titled 'Dystrophic Epidermolysis Bullosa Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity and Forecast'. Dystrophic epidermolysis bullosa refers to a rare genetic condition that causes the skin to blister or tear easily. The response could be to a minor injury or friction, such as rubbing or scratching or even from heat. The signs and symptoms of dystrophic epidermolysis bullosa generally differ among individuals. In mild cases, blistering may affect hands, feet, knees, and elbows, while in severe cases, widespread blistering occurs, which leads to scarring, vision loss, and other medical problems. The disease is diagnosed by identifying biallelic pathogenic variants (RDEB) or a heterozygous pathogenic variant (DDEB) in COL7A1 by molecular genetic testing. Currently, the available treatment focuses on managing symptoms and complications. Some of the common treatment available for dystrophic epidermolysis bullosa, include moisturizers to lessen friction and irritation, non-adhesive bandages and dressings to protect the wound, and medicines to ease the pain.

The rising incidences of rare genetic disorders coupled with the inflating demand for novel medications that can treat the conditions effectively are primarily driving the global dystrophic epidermolysis bullosa market. Besides this, the increasing patient willingness to pay for expensive treatments, such as gene therapy, cell-based therapy, molecular

therapy, etc., is further augmenting the global market. Moreover, the emerging popularity of non-adhesive semiocclusive dressings, including soft silicone and foam dressings, for treating dystrophic epidermolysis bullosa since they absorb exudate and reduce pain and blister formation during dressing is also acting as another growth-inducing factor. In addition to this, numerous stakeholders are making significant investments in R&D activities to gain a clear understanding of the disease etiopathogenesis for developing new and cutting-edge therapy alternatives. This, in turn, is further creating a positive outlook for the market. Furthermore, the introduction of several treatment alternatives, such as stem cell transplantation and gene correction, is also bolstering the market growth. Additionally, the escalating need for more effective and personalized therapies with improved long-term side effect profiles is further expected to bolster the global dystrophic epidermolysis bullosa market in the coming years.

IMARC Group's new report 'Dystrophic Epidermolysis Bullosa Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity and Forecast' provides an exhaustive analysis of the Dystrophic Epidermolysis Bullosa market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The report provides an in-depth understanding of current and future landscape of the Dystrophic Epidermolysis Bullosa market. This includes treatment practices, in-market and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool for Dystrophic Epidermolysis Bullosa across the seven major markets. According to the report the United States has the largest patient pool for Dystrophic Epidermolysis Bullosa and also represents the largest market for Dystrophic Epidermolysis Bullosa treatment. Furthermore, the current Dystrophic Epidermolysis Bullosa treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Dystrophic Epidermolysis Bullosa market in any manner.

Time Period of the Study

Base Year: 2022

Historical Period: 2017-2022

Market Forecast: 2023-2033

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, Current and Future Epidemiology Scenario
Historical, Current and Future Performance of the Dystrophic Epidermolysis Bullosa Market
Historical, Current and Future Performance of Various Therapeutic Categories in the Dystrophic Epidermolysis Bullosa Market
Sales of Various Drugs Across the Dystrophic Epidermolysis Bullosa Market
Reimbursement Scenario in the Dystrophic Epidermolysis Bullosa Market
In-Market and Pipeline Drugs

This report also provides a detailed analysis of the current Dystrophic Epidermolysis Bullosa marketed drugs and late-stage pipeline drugs.

In-Market Dystrophic Epidermolysis Bullosa Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Dystrophic Epidermolysis Bullosa Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results

Regulatory Status

Key Questions Answered in this Report

Market Insights

How has the Dystrophic Epidermolysis Bullosa market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2022 and how are they expected to be in 2033?

What was the country-wise size of the Dystrophic Epidermolysis Bullosa market across the seven major markets in 2022 and how will it look like in 2033?

What is the growth rate of the Dystrophic Epidermolysis Bullosa market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the Dystrophic Epidermolysis Bullosa market?

Epidemiology Insights

What is the size of the Dystrophic Epidermolysis Bullosa patient pool (2017-2022) across the seven major markets?

What would be the forecasted patient pool (2023-2033) of Dystrophic Epidermolysis Bullosa across the seven major markets?

What are the key factors driving the epidemiological trend of Dystrophic Epidermolysis Bullosa?

What will be the growth rate of Dystrophic Epidermolysis Bullosa patients across the seven major markets?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed Dystrophic Epidermolysis Bullosa drugs and what are their market performance?

What are the key pipeline Dystrophic Epidermolysis Bullosa drugs and how are they expected to perform in the coming years?

How safe are the current marketed Dystrophic Epidermolysis Bullosa drugs and what are their efficacies?

How safe are the late-stage pipeline Dystrophic Epidermolysis Bullosa drugs and what are their efficacies?

What are the current treatment guidelines for Dystrophic Epidermolysis Bullosa drugs across the seven major markets?

Who are the key companies in the Dystrophic Epidermolysis Bullosa market and what

are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Dystrophic Epidermolysis Bullosa market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 DYSTROPHIC EPIDERMOLYSIS BULLOSA - INTRODUCTION

- 4.1 Overview
- 4.2 Epidemiology (2017-2022) and Forecast (2023-2033)
- 4.3 Market Overview (2017-2022) and Forecast (2023-2033)
- 4.4 Competitive Intelligence

5 DYSTROPHIC EPIDERMOLYSIS BULLOSA - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 DYSTROPHIC EPIDERMOLYSIS BULLOSA - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

7.2 Epidemiology Scenario - Top 7 Markets

7.2.1 Epidemiology Scenario (2017-2022)

7.2.2 Epidemiology Forecast (2023-2033)

7.3 Epidemiology Scenario - United States

7.3.1 Epidemiology Scenario (2017-2022)

7.3.2 Epidemiology Forecast (2023-2033)

7.4 Epidemiology Scenario - Germany

7.4.1 Epidemiology Scenario (2017-2022)

7.4.2 Epidemiology Forecast (2023-2033)

7.5 Epidemiology Scenario - France

7.5.1 Epidemiology Scenario (2017-2022)

7.5.2 Epidemiology Forecast (2023-2033)

7.6 Epidemiology Scenario - United Kingdom

7.6.1 Epidemiology Scenario (2017-2022)

7.6.2 Epidemiology Forecast (2023-2033)

7.7 Epidemiology Scenario - Italy

7.7.1 Epidemiology Scenario (2017-2022)

7.7.2 Epidemiology Forecast (2023-2033)

7.8 Epidemiology Scenario - Spain

7.8.1 Epidemiology Scenario (2017-2022)

7.8.2 Epidemiology Forecast (2023-2033)

7.9 Epidemiology Scenario - Japan

7.9.1 Epidemiology Scenario (2017-2022)

7.9.2 Epidemiology Forecast (2023-2033)

8 DYSTROPHIC EPIDERMOLYSIS BULLOSA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

8.1 Dystrophic Epidermolysis Bullosa Guidelines, Management and Treatment

8.2 Dystrophic Epidermolysis Bullosa Treatment Algorithm

9 DYSTROPHIC EPIDERMOLYSIS BULLOSA - UNMET NEEDS

10 DYSTROPHIC EPIDERMOLYSIS BULLOSA - KEY ENDPOINTS OF TREATMENT

11 DYSTROPHIC EPIDERMOLYSIS BULLOSA - MARKETED PRODUCTS

11.1 List of Dystrophic Epidermolysis Bullosa Marketed Drugs Across the Top 7 Markets

- 11.1.1 Filsuvez (Birch triterpenes) - Amryt Pharma
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets

12 DYSTROPHIC EPIDERMOLYSIS BULLOSA - PIPELINE DRUGS

- 12.1 List of Dystrophic Epidermolysis Bullosa Pipeline Drugs Across the Top 7 Markets
 - 12.1.1 Dabocemagene autoficel - Fibrocell Science
 - 12.1.1.1 Drug Overview
 - 12.1.1.2 Mechanism of Action
 - 12.1.1.3 Clinical Trial Results
 - 12.1.1.4 Safety and Efficacy
 - 12.1.1.5 Regulatory Status
 - 12.1.2 Beremagene geperpavec - Krystal Biotech
 - 12.1.2.1 Drug Overview
 - 12.1.2.2 Mechanism of Action
 - 12.1.2.3 Clinical Trial Results
 - 12.1.2.4 Safety and Efficacy
 - 12.1.2.5 Regulatory Status
 - 12.1.3 EB-101 - Abeona Therapeutics
 - 12.1.3.1 Drug Overview
 - 12.1.3.2 Mechanism of Action
 - 12.1.3.3 Clinical Trial Results
 - 12.1.3.4 Safety and Efficacy
 - 12.1.3.5 Regulatory Status
 - 12.1.4 PTR-01 - Phoenix Tissue Repair
 - 12.1.4.1 Drug Overview
 - 12.1.4.2 Mechanism of Action
 - 12.1.4.3 Clinical Trial Results
 - 12.1.4.4 Safety and Efficacy
 - 12.1.4.5 Regulatory Status
 - 12.1.5 Timbetasin - RegeneRx Biopharmaceuticals
 - 12.1.5.1 Drug Overview
 - 12.1.5.2 Mechanism of Action
 - 12.1.5.3 Clinical Trial Results
 - 12.1.5.4 Safety and Efficacy

12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs and the complete list has been provided in the report

13 DYSTROPHIC EPIDERMOLYSIS BULLOSA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14 DYSTROPHIC EPIDERMOLYSIS BULLOSA - MARKET SCENARIO

14.1 Market Scenario - Key Insights

14.2 Market Scenario - Top 7 Markets

14.2.1 Dystrophic Epidermolysis Bullosa - Market Size

14.2.1.1 Market Size (2017-2022)

14.2.1.2 Market Forecast (2023-2033)

14.2.2 Dystrophic Epidermolysis Bullosa - Market Size by Therapies

14.2.2.1 Market Size by Therapies (2017-2022)

14.2.2.2 Market Forecast by Therapies (2023-2033)

14.3 Market Scenario - United States

14.3.1 Dystrophic Epidermolysis Bullosa - Market Size

14.3.1.1 Market Size (2017-2022)

14.3.1.2 Market Forecast (2023-2033)

14.3.2 Dystrophic Epidermolysis Bullosa - Market Size by Therapies

14.3.2.1 Market Size by Therapies (2017-2022)

14.3.2.2 Market Forecast by Therapies (2023-2033)

14.3.3 Dystrophic Epidermolysis Bullosa - Access and Reimbursement Overview

14.4 Market Scenario - Germany

14.4.1 Dystrophic Epidermolysis Bullosa - Market Size

14.4.1.1 Market Size (2017-2022)

14.4.1.2 Market Forecast (2023-2033)

14.4.2 Dystrophic Epidermolysis Bullosa - Market Size by Therapies

14.4.2.1 Market Size by Therapies (2017-2022)

14.4.2.2 Market Forecast by Therapies (2023-2033)

14.4.3 Dystrophic Epidermolysis Bullosa - Access and Reimbursement Overview

14.5 Market Scenario - France

14.5.1 Dystrophic Epidermolysis Bullosa - Market Size

14.5.1.1 Market Size (2017-2022)

14.5.1.2 Market Forecast (2023-2033)

14.5.2 Dystrophic Epidermolysis Bullosa - Market Size by Therapies

14.5.2.1 Market Size by Therapies (2017-2022)

- 14.5.2.2 Market Forecast by Therapies (2023-2033)
- 14.5.3 Dystrophic Epidermolysis Bullosa - Access and Reimbursement Overview
- 14.6 Market Scenario - United Kingdom
 - 14.6.1 Dystrophic Epidermolysis Bullosa - Market Size
 - 14.6.1.1 Market Size (2017-2022)
 - 14.6.1.2 Market Forecast (2023-2033)
 - 14.6.2 Dystrophic Epidermolysis Bullosa - Market Size by Therapies
 - 14.6.2.1 Market Size by Therapies (2017-2022)
 - 14.6.2.2 Market Forecast by Therapies (2023-2033)
 - 14.6.3 Dystrophic Epidermolysis Bullosa - Access and Reimbursement Overview
- 14.7 Market Scenario - Italy
 - 14.7.1 Dystrophic Epidermolysis Bullosa - Market Size
 - 14.7.1.1 Market Size (2017-2022)
 - 14.7.1.2 Market Forecast (2023-2033)
 - 14.7.2 Dystrophic Epidermolysis Bullosa - Market Size by Therapies
 - 14.7.2.1 Market Size by Therapies (2017-2022)
 - 14.7.2.2 Market Forecast by Therapies (2023-2033)
 - 14.7.3 Dystrophic Epidermolysis Bullosa - Access and Reimbursement Overview
- 14.8 Market Scenario - Spain
 - 14.8.1 Dystrophic Epidermolysis Bullosa - Market Size
 - 14.8.1.1 Market Size (2017-2022)
 - 14.8.1.2 Market Forecast (2023-2033)
 - 14.8.2 Dystrophic Epidermolysis Bullosa - Market Size by Therapies
 - 14.8.2.1 Market Size by Therapies (2017-2022)
 - 14.8.2.2 Market Forecast by Therapies (2023-2033)
 - 14.8.3 Dystrophic Epidermolysis Bullosa - Access and Reimbursement Overview
- 14.9 Market Scenario - Japan
 - 14.9.1 Dystrophic Epidermolysis Bullosa - Market Size
 - 14.9.1.1 Market Size (2017-2022)
 - 14.9.1.2 Market Forecast (2023-2033)
 - 14.9.2 Dystrophic Epidermolysis Bullosa - Market Size by Therapies
 - 14.9.2.1 Market Size by Therapies (2017-2022)
 - 14.9.2.2 Market Forecast by Therapies (2023-2033)
 - 14.9.3 Dystrophic Epidermolysis Bullosa - Access and Reimbursement Overview

15 DYSTROPHIC EPIDERMOLYSIS BULLOSA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

16 DYSTROPHIC EPIDERMOLYSIS BULLOSA MARKET - SWOT ANALYSIS

16.1 Strengths

16.2 Weaknesses

16.3 Opportunities

16.4 Threats

17 APPENDIX

I would like to order

Product name: Dystrophic Epidermolysis Bullosa Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2033

Product link: <https://marketpublishers.com/r/DF050A072A6DEN.html>

Price: US\$ 5,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/DF050A072A6DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

